NASDAQ · Biotechnology · USD

GH Research PLC (GHRS) Stock Analysis

GH Research PLC (GHRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GHRS

$18.91

−$0.25 (−1.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GHRS with… →

GHRS Key Statistics

As of Oct 21, 2026

Trading

Open: $19.22
Previous Close: $19.17
Day's Range: 18.81–19.81
52-Week Range: 12.04–31.44
Volume: 393.79K
Beta: 1.33

Valuation

Market Cap: $1.30B
P/E Ratio: unprofitable
EPS (ttm): −0.99

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$48.26M
Shares Outstanding: 68.64M
1-Year Return: +48.20%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 280.27K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GHRS closed at $18.91, +48.20% over 1 year.

GH Research PLC (GHRS) has a market capitalization of $1.30B.

In fiscal 2025, GHRS reported revenue of $0.00.

GHRS Stock Return by Calendar Year

GH Research PLC (GHRS) return since Jun 2021: what $10,000 became

1 year: $10,000 $14,820; +48.20%
5 years: $10,000 $13,411; +34.11%
Since Jun 2021: $10,000 $9,823; −1.77%

If you had invested $10,000 in GH Research PLC (GHRS) at the close on June 25, 2021, the earliest close on record here, it would have been worth $9,823 at the close on October 21, 2026: −1.77% in total, −0.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+21.19%−58.34%−40.33%+20.69%+81.43%+48.90%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+48.90%
2025	+81.43%
2024	+20.69%
2023	−40.33%
2022	−58.34%
2021 (partial year)	+21.19%

As of October 21, 2026.

GHRS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$48.26M	—
2024	$0.00	−$38.96M	—
2023	$0.00	−$35.59M	—
2022	$0.00	−$22.46M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$60.68M	−$48.26M	—
2024	$0.00	—	−$50.25M	−$38.96M	—
2023	$0.00	—	−$41.22M	−$35.59M	—
2022	$0.00	—	−$30.68M	−$22.46M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

GH Research PLC (GHRS) carries a market capitalisation of $1.30B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

GHRS last closed at $18.91 on October 21, 2026. That is −$0.25 (−1.33%) against the previous close. The 52-week range on file runs from $12.04 to $31.44. The latest close sits 57.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $48.26M. Trailing earnings per share are −0.99.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.33. Daily returns over the trailing 5 years annualize to a volatility of 85.99%. Over the trailing twelve months the total return is +48.20%. Across 5 years the annualized return works out at +6.05%.

Growth & Income

The record shows no dividend for GHRS.

The strongest complete calendar year on file is 2025 at +81.43%; the weakest is 2022 at −58.34%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +48.90% year to date.

Peer Comparison

GH Research PLC (GHRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
GH Research PLC	GHRS	$1.30B	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. GH Research PLC has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About GH Research PLC

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Visit website →